港股異動丨東陽光藥漲逾5% 三季度業績大勝預期 券商唱多
格隆匯10月29日丨東陽光藥(1558.HK)漲逾5%,報46.75港元,成交1.14億港元,總市值210億港元。東陽光藥前三季度收入為44.4億元人民幣,同比增長158%。銀河國際研報認為,業績強勁增長主要是由於可威銷售大增,受惠於公司加強了學術推廣和擴大了較低級別醫院的銷售渠道。毛利率從84%改善至2019年首九個月的85.5%,主要由於可威銷售增加。前三季度淨利為13.2億元人民幣,同比增長93.4%,分別佔銀河國際和市場共識對2019年全年預測的99%/96%,反映其業績明顯優於市場預期。季度數據方面,2019年三季度收入為13.7億元人民幣,同比增長470%,利潤為3.51億元人民幣,同比增長632%。銀河國際將其目標價從48.9港元上調至53.1港元。國金證券上週末發表報告預測2019年東陽光藥營業總收入和歸母淨利潤分別為55.98億元、18.25億元。維持對東陽光藥的“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.